The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus
NCT ID: NCT04091854
Last Updated: 2021-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
24 participants
OBSERVATIONAL
2018-12-12
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
NCT03141073
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
NCT02386982
Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
NCT02597400
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers
NCT04426708
The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM
NCT02765347
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HMS5552 treatment
HMS5552
To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HMS5552
To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c \< 8.0% was detected in our laboratory;
* Researchers judged the stability of glucose control based on the data of subjects'visits during HMS5552 treatment and the indicators of our hospital;
* Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise;
* Willing to sign written informed consent and abide by the research program.
Exclusion Criteria
* The researchers judged that subjects'compliance with HMS5552 was affected during treatment.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Majianhua
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Majianhua
Director, Head of Endocrinology department, Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20190530-01-KS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.